Head and Neck Pathology

, Volume 1, Issue 2, pp 132–140 | Cite as

Bisphosphonate-related Osteonecrosis of the Jaws: An Update on Clinical, Pathological and Management Aspects

Review Paper

Abstract

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly observed in patients with multiple myeloma and bone metastasis from solid tumors receiving iv bisphosphonate therapy. The reported incidence of BRONJ is significantly higher with the iv preparations zoledronic acid and pamidronate while the risk appears to be minimal for patients receiving oral bisphosphonates. Currently available published incidence data for BRONJ are based on retrospective studies and estimates of cumulative incidence range from 0.8 to 12%. The mandible is more commonly affected than the maxilla (2:1 ratio), and 60–70% of cases are preceded by a dental surgical procedure. The signs and symptoms that may occur before the appearance of clinical evident osteonecrosis include changes in the health of periodontal tissues, non-healing mucosal ulcers, loose teeth and unexplained soft-tissue infection. Although the definitive role of bisphosphonates remains to be elucidated, the inhibition of physiologic bone remodeling and angiogenesis by these potent drugs impairs the regenerative capacity of the bone causing the development of BRONJ. Tooth extraction as a precipitating event is a common observation. The significant benefits that bisphosphonates offer to patients clearly surpass the risk of potential side effects; however, any patient for whom prolonged bisphosphonate therapy is indicated, should be provided with preventive dental care in order to minimize the risk of developing this severe condition. This article provides an update review of current knowledge about clinical, pathological and management aspects of BRONJ.

Keywords

Bisphosphonate Osteonecrosis Jaws Osteomyelitis Zoledronic acid Pamidronate Cancer Bone metastasis Osteoporosis Review 

References

  1. 1.
    Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in cancer patients. Acta Oncol 2007;46:581–91PubMedCrossRefGoogle Scholar
  2. 2.
    Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104–7PubMedCrossRefGoogle Scholar
  3. 3.
    Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg 2003;61:60 (letter)CrossRefGoogle Scholar
  4. 4.
    Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115–7 (letter)PubMedCrossRefGoogle Scholar
  5. 5.
    Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. New Engl J Med 2003;21:4253–4 (letter)Google Scholar
  6. 6.
    Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527–34PubMedCrossRefGoogle Scholar
  7. 7.
    Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004;117:440–1PubMedCrossRefGoogle Scholar
  8. 8.
    Bagan JV, Murillo J, Poveda R, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120–3PubMedCrossRefGoogle Scholar
  9. 9.
    Vannucchi AM, Ficarra G, Antonioli E, et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005;128:738 (letter)PubMedCrossRefGoogle Scholar
  10. 10.
    Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123–8PubMedCrossRefGoogle Scholar
  11. 11.
    Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83–93PubMedCrossRefGoogle Scholar
  12. 12.
    Merigo E, Manfredi M, Meleti M, et al. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four- case report. J Oral Pathol Med 2005;34:613–7PubMedCrossRefGoogle Scholar
  13. 13.
    Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005;66:658PubMedCrossRefGoogle Scholar
  14. 14.
    Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620–3PubMedCrossRefGoogle Scholar
  15. 15.
    Sanna G, Preda L, Bruschini R, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006;17:1512–6PubMedCrossRefGoogle Scholar
  16. 16.
    Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945–52PubMedCrossRefGoogle Scholar
  17. 17.
    Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753–61PubMedGoogle Scholar
  18. 18.
    Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonates treatment. Lancet Oncol 2006;7:508–14PubMedCrossRefGoogle Scholar
  19. 19.
    Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Pathol Oral Med 2006;102:433–41CrossRefGoogle Scholar
  20. 20.
    Bilezikian JP. Osteonecrosis of the jaw-Do bisphosphonates pose a risk? N Engl J Med 2006;355:2278–81PubMedCrossRefGoogle Scholar
  21. 21.
    Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risk and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nature Clin Pract Oncol 2007;4:42–55CrossRefGoogle Scholar
  22. 22.
    Phal PM, Myall RW, Assael LA, et al. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 2007;28:1139–45PubMedCrossRefGoogle Scholar
  23. 23.
    Body J-J, Coleman R, Clezardin P, et al. International society of geriatric oncology (SIOG) clinical practice recommendation for the use of bisphosphonates in elderly patients. Eur J Cancer 2007;43:852–8PubMedCrossRefGoogle Scholar
  24. 24.
    Weitzman R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 2007;62:148–52PubMedCrossRefGoogle Scholar
  25. 25.
    Dannemann C, Gratz KW, Riener MO, et al. Jaw osteonecrosis related to bisphosphonates therapy. A severe secondary disorder. Bone 2007;40:828–34PubMedCrossRefGoogle Scholar
  26. 26.
    Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laringoscope 2006;116:115–20CrossRefGoogle Scholar
  27. 27.
    Brooks JK, Gilson AJ, Sindler AG, et al. Osteonecrosis of the jaws associated with use of risendronate: report of 2 new cases. Oral Sur Oral Med Oral Pathol 2007;103:780–6CrossRefGoogle Scholar
  28. 28.
    Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonates treatment. J Am Dent Assoc 2006;137:1115–9PubMedGoogle Scholar
  29. 29.
    Senel FC, Tekin US, Durmus A, et al. Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonates (disodium clodronate): report of a case. J Oral Maxillofac Surg 2007;65:562–5PubMedCrossRefGoogle Scholar
  30. 30.
    Montazeri AH, Erskine JG, McQuaker IG. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 2007;79:69–71PubMedCrossRefGoogle Scholar
  31. 31.
    Yarom N, Yahalom Y, Shoshani, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18(10):1363–70PubMedCrossRefGoogle Scholar
  32. 32.
    Barmias A, Kastritis E, Bamia C, et al. Ostenecrosis of the jaws in cancer after treatment bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580–7CrossRefGoogle Scholar
  33. 33.
    Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65:1328–31PubMedCrossRefGoogle Scholar
  34. 34.
    Wilkinson GS, Kuo Y-F, Freeman JL, et al. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007;99:1016–24PubMedCrossRefGoogle Scholar
  35. 35.
    Miles AE. Phosphorus necrosis of the jaw: “phossy jaw”. Br Dent J 1972;133:203–6PubMedCrossRefGoogle Scholar
  36. 36.
    Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682–9PubMedCrossRefGoogle Scholar
  37. 37.
    Wong JK, Wood RE, McClean M. Conservative management of osteoradionecrosis . Oral Surg Oral Med Oral Pathol 1997;84:16–21Google Scholar
  38. 38.
    Epstein J, van der Meij E, McKenzie M, et al. Postradiation necrosis of the mandible: a long term follow-up study. Oral Surg Oral Med Oral Pathol 1997;83:657–62Google Scholar
  39. 39.
    Schwartz HC. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 1982;4:251–3PubMedCrossRefGoogle Scholar
  40. 40.
    Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associate osteonecrosis of the auditory canal. Br J Haematol 2006;132:114PubMedCrossRefGoogle Scholar
  41. 41.
    Silverman SL, Maricic M. Recent developments in bisphosphonates therapy. Semin Arthritis Rheum 2007;37(1):1–12PubMedCrossRefGoogle Scholar
  42. 42.
    Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 2007;36:319–38PubMedCrossRefGoogle Scholar
  43. 43.
    Reid IR, Bolland MJ. Is bisphosphonates-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41:318–20PubMedCrossRefGoogle Scholar
  44. 44.
    Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zolendronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007;21:1545–8PubMedCrossRefGoogle Scholar
  45. 45.
    Kamaisi M, Regegev E, Yarom N, et al. Possible association between diabetes and bisphosphonates-related jaw osteonecrosis. J Clin Endocrinol Metab 2006;92:1172–5CrossRefGoogle Scholar
  46. 46.
    Tada A, Senpuku H, Motozawa Y, et al. Association between commensal bacteria and opportunistic pathogens in the dental plaque of elderly individuals. Clin Microbiol Infect 2006;12:776–81PubMedGoogle Scholar
  47. 47.
    Bullough P. Osteonecrosis and bone infarction. In: Bullogh P, editor Orthopaedic pathology. 4th ed. Edinburgh: Mosby; 2004. p. 347–62Google Scholar
  48. 48.
    Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006; 35:155–60PubMedCrossRefGoogle Scholar
  49. 49.
    Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457–63PubMedCrossRefGoogle Scholar
  50. 50.
    Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:269–79CrossRefGoogle Scholar
  51. 51.
    Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telepeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000;85:3537–40PubMedCrossRefGoogle Scholar
  52. 52.
    von Schewelov T, Carlsson A, Dahlberg L. Cross-linked N-telopeptide of type I collagen (NTx) in urine as predictor of periprosthetic osteolysis. J Orthop Res 2006;24:1342–8CrossRefGoogle Scholar
  53. 53.
    American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonates-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369–76Google Scholar
  54. 54.
    Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking bisphosphonates. Joint Bone Spine 2006;73:7–9PubMedCrossRefGoogle Scholar
  55. 55.
    Van den Wyngaert T, Manon TU, Vermorken JB. Osteonecrosis of the jaw related to use of bisphosphonates. Curr Opin Oncol 2007;19:315–22PubMedCrossRefGoogle Scholar
  56. 56.
    Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonates-induced exposed bone of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567–75PubMedCrossRefGoogle Scholar
  57. 57.
    Thakkar SG, Isada C, Smith J, et al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 2006;23:51–6PubMedCrossRefGoogle Scholar
  58. 58.
    Pires FR, Mirando A, Cardoso ES, et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 2005;11:365–9PubMedCrossRefGoogle Scholar
  59. 59.
    Montebugnoli L, Felicetti L, Gissi B, et al. Bisphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol 2007;104:473–7Google Scholar
  60. 60.
    Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 2007;138:971–7PubMedGoogle Scholar
  61. 61.
    Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonates-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007;65:1321–7PubMedCrossRefGoogle Scholar
  62. 62.
    Agrillo A, Petrucci MT, Tedaldi M, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. J Cranio Surg 2006;17:1080–3CrossRefGoogle Scholar
  63. 63.
    Vescovi P, Merigo E, Meleti M, et al. Nd:YAG laser biostimulation of bisphosphonateassociated necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg 2007); (electronic version-in press)Google Scholar
  64. 64.
    Krueger CD, West PM, Sargent M, et al. Bisphosphonates-induced osteonecrosis of the jaws. Ann Pharmacother 2007;41:276–84PubMedCrossRefGoogle Scholar

Copyright information

© Humana 2007

Authors and Affiliations

  1. 1.Reference Center for the Study of Oral DiseasesUniversity of FlorenceFlorenceItaly
  2. 2.Azienda Ospedaliero-Universitaria CareggiFlorenceItaly
  3. 3.Department of Odonto-StomatologyUniversity of FlorenceFlorenceItaly

Personalised recommendations